A STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TMC435 IN COMBINATION WITH PEGIFN ALFA-2A (PEGASYS) AND RIBAVIRIN (COPEGUS) IN TREATMENT-NAÏVE OR TREATMENT-EXPERIENCED, CHRONIC HEPATITIS C VIRUS GENOTYPE-4 INFECTED PATIENTS: